Amgen (NASDAQ:AMGN) executives said the company delivered a “strong first quarter” and remains positioned to meet its goals ...
Amgen has pulled the plug on midstage drug candidates for cancer and the autoimmune disease Sjögren’s syndrome, terminating ...
Amgen Inc. reported better-than-expected first-quarter results even as some newer drugs that analysts expect to drive growth over the next few years underperformed.
By Deena Beasley April 30 (Reuters) - Amgen on Thursday reported first-quarter product sales rose 4%, helped by demand for ...
The FDA’s real-time clinical trial mechanism allows drug sponsors to transmit data immediately to the regulator through the ...
The FDA has renewed calls for Amgen’s Tavneos to be pulled from the market, saying it has discovered new evidence that study ...
Atlassian and Amgen both reported quarterly earnings and revenue ahead of analyst expectations, driven by AI adoption, enterprise expansion, and strong product sales. Meanwhile, WARN filings show ...
How Amgen’s Recent Share Performance Frames the Story Amgen (AMGN) has drawn attention after recent share price weakness, ...
Earlier this year, when the FDA asked Amgen to pull its rare disease drug Tavneos from the market, the California drugmaker ...
The Dow Jones Industrial Average was roughly split ahead of the closing bell between components in the green and those in the red. But big losses from Amgen and McDonald's were weighing on the ...
Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results